Cullinan To Search For Oncology’s Diamonds In The Rough

With a business model based on portfolio management, the new company backed by MPM Capital plans to de-risk novel cancer therapies for out-licensing upon proof-of-concept or other value-creating inflection points.

Owen Hughes, CEO of Cullinan Oncology, and Patrick Bauerle, chief scientific officer of Cullinan
Cullinan CEO Owen Hughes, CSO Biologics Patrick Bauerle • Source: Source: Cullinan Oncology LLC

Privately held Cullinan Oncology LLC is launching with a $150m Series A financing, using a model of taking stand-alone cancer projects that other companies might turn down as too risky through Phase II proof-of-concept, and then – hopefully – monetizing them.

Backed by MPM Capital and F2 Ventures, Cullinan derives from the former’s UBS Oncology Impact Fund (IOF) as well as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By 

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Finance Watch: Two New Venture Capital Funds Provide $600m For Biopharma

 
• By 

Private Company Edition: Catalio raised more than $400m for its fourth health care-focused VC fund, while AN Venture Partners raised $200m for Japan and beyond. In VC financings, among a dearth of mega rounds, Neuron23’s $96.5m series D is the largest round in recent weeks.

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

 

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.

More from Business